Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

NCT04233021 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic
Leptomeningeal Metastasis
Brain Metastases
EGFR Activating Mutation

Interventions

DRUG: Osimertinib

Sponsor

Intergroupe Francophone de Cancerologie Thoracique